



## POINT OF VIEW

# Antimicrobial stewardship programs in the critical care setting



## Programas de administración de antimicrobianos en la unidad de cuidados intensivos

J. Ruiz-Ramos, P. Ramirez\*

*Intensive Care Unit, Hospital Universitario y Politecnico La Fe, Spain*

Received 14 March 2016; accepted 24 April 2016

Available online 2 July 2016

The increase in bacterial resistance to antibiotics is one of the greatest threats to global health. This problem is especially relevant in critical care units, where the number of isolates of multiresistant species grow each year<sup>1</sup> reducing the number of alternatives available to treat serious infectious diseases such as sepsis, meningitis or nosocomial pneumonia. Moreover, despite promises and efforts to create new antimicrobials, currently there are little effective developments in the pharmaceutical market.

The spread of multidrug-resistant microorganisms (MDRM) is due to the failure of the measures to prevent cross-transmission but also to the continuous genesis of new resistances. It has been repeatedly shown that the generation of resistance is closely related to exposure to antimicrobials.<sup>2</sup> In this sense, what is most striking is that even 30–50% of prescriptions of antibiotics may be unnecessary.<sup>3</sup>

All this has sponsored the development of so-called Antimicrobial Stewardship Programs (ASP) (*Programas de Optimización de Antimicrobianos* (PROA) in Spanish). These

programs include a set of activities intended to optimize the antimicrobial treatment, ensuring the best clinical outcome for the patient but avoiding where possible the development of antimicrobial resistance. The latter objective is largely based on the elimination of all those unfair treatments and on the replacement of broad-spectrum drugs when possible. This type of programs is being implemented in hospitals around the world, proving to be a useful tool in reducing the consumption of antimicrobials and the reduction of bacterial resistance. However, its implementation in critical care units has an added difficulty because of several factors such as patient severity, high MDRM prevalence and pharmacokinetic–pharmacodynamic particularities. However, several works in critical patients have shown the success of the ASP. Examples are the results obtained by Elligsen et al. who achieved a 23% reduction in consumption of antimicrobials and also succeeded an improvement in sensitivity to meropenem.<sup>4</sup> Also noteworthy is the work of Rimaway et al., who, in addition to a reduction in broad-spectrum antibiotics consumption, achieved a diminution in the days of mechanical ventilation and length of stay in the unit.<sup>5</sup> Other studies published in critically ill patients have shown a significant reduction in the use of antimicrobials.

\* Corresponding author.

E-mail address: [ramirez\\_pau@gva.es](mailto:ramirez_pau@gva.es) (P. Ramirez).




Figure 1 Antimicrobial stewardship program operating strategy.

Nevertheless, we do not yet have sufficient scientific evidence to show a positive impact of ASP on the evolution of critically patients and their ecological environment. In fact, in a recent review Mertz et al. underscore this fact by the low methodological quality of the studies published to date.<sup>6</sup> We should note the great difficulty of achieving an effect on hospital stay or mortality due to the multitude of factors that influence the prognosis of critically ill patients. Furthermore, an ASP applied exclusively in the critical care unit could hardly have an effect on the occurrence of bacterial resistance due to the continuous movement of patients with the rest of the hospital. However, given the impact of these programs on antimicrobial consumption and the relationship between antibiotic use and resistance, ASP should be implemented in all critical care units.

ASP format may be different but should be directed to the early stages of antibiotic treatment, should include joint assessment between the pharmacist and the medical care and should conclude with a feedback to the doctor who prescribed the treatment. ASP in ICUs should be led by a specialist in hospital pharmacy in tandem with an intensivist specially dedicated to the field of infection, but must have the support of other specialties such as microbiology and infectious as well as a clear institutional support.<sup>7</sup> Factors that should be evaluated include drug de-escalation to a lower therapeutic spectrum, duration of treatment, pharmacokinetic–pharmacodynamics characteristics

and possible interactions (Fig. 1). By feedback to the prescriber the ASP will also achieve a progressive educational effect.

### Antimicrobial de-escalation

In much of the infectious processes the antimicrobial spectrum of the initially chosen drugs can be safely reduced following MDRM rule out in the microbiological analysis. This strategy has proven to be safe for patient outcome.<sup>8</sup> In fact, broad-spectrum antimicrobial agents should be reserved for patients with risk factors for MDRM infection (empirical treatment) or before the isolation of a MDRM in clinically representative samples (targeted therapy).

Antimicrobials may also be de-escalated in terms of its number. The combination of antibiotics is one strategy that increases the likelihood of achieving an appropriate empirical treatment. However, once an etiologic diagnosis has been achieved, the combination should be restricted to those cases where the characteristics of the host, the infection, the drug or the microorganism make unlikely to achieve the pharmacokinetic–pharmacodynamic target. An example of this situation could be a severely ill patient with a ventilator-associated pneumonia caused by *Pseudomonas aeruginosa* susceptible exclusively to colistin and fosfomycin; both drugs have a low lung penetration,

*P aeruginosa* is a typically difficult to eradicate microorganism and the patient is in a critical condition. In this example monotherapy would have little chance of effectiveness and otherwise there would be a high risk of induction of new resistances.

In any case, it must be noted that in most of clinical trials and published meta-analysis, combination therapy has shown little benefit over monotherapy and has proved in many cases an increase in drug toxicity.<sup>9</sup> ASP teams should carefully evaluate the desirability for combined treatment and the duration thereof.

### Antimicrobial treatment duration

Shorten the duration of antimicrobial treatment is one of the main tasks of the ASP team as prolonged treatments are a key element in the genesis of resistance. The prolonged antibiotic treatment often leads to colonization by MDRDM and the possible emergence of recurrent of infection.

Most of the episodes of nosocomial pneumonia or bacteraemia in immunocompetent patients have a good outcome after seven days of treatment and stopping treatment is safe at that time.<sup>10</sup>

Over the past several years, biomarkers have been studied in relation to infection in critically ill patients, among them procalcitonin. Procalcitonin has been studied in several clinical trials and, although the results have not been entirely homogeneous, this biomarker seems to be useful to safely shorten antibiotic treatment.<sup>11</sup>

### Pharmacokinetic/pharmacodynamics optimization

The critical patient suffers major pathophysiological changes that alter the plasma and tissue concentrations of most antimicrobials. Acute renal failure, liver failure and reduced local blood flow can cause an accumulation of drugs and therefore toxicity. Moreover, more frequent is the increase in the volume of distribution of hydrophilic antimicrobials (due to volume overload and oedema) causing a decrease in plasma concentrations and consequent therapeutic failure.<sup>12</sup>

These pharmacokinetic changes must be added to the progressive increase of the minimum inhibitory concentration (MIC) to various antibiotics of many microorganisms, mainly for Gram-negative species, making it more difficult to obtain an adequate antimicrobial exposure in pharmacodynamic terms.<sup>13</sup>

ASP teams should include experts in pharmacokinetic/pharmacodynamic variables when advising on the most appropriate drug and dosage for critically ill patients.

### Communication with the attending physician

Communication (feedback) with the prescribing physician is key element for the ASP success. Feedback can be set by technological means or by personal interview but in any case must be based on mutual respect, attitude

to dialogue and on the establishment of agreements if necessary.

Only in the absence of cooperation or in situations of high clinical or epidemiological risk, the mode of action of the ASP team could be that the imposition or restriction of antimicrobial treatments and in these cases the team will need an institutional support.

### Conclusions

ASPs in intensive care units, in coordination with nosocomial infection control teams, are able to reduce and optimize antimicrobial therapies. The need to preserve antimicrobials given the lack of alternatives and the expansion of MDRM makes it essential to implement such programs in all critical care units. To ensure the success of these programs it is required the participation of a multidisciplinary team, the use of educational measures, an adequate system of periodic indicators and results and an adequate feedback to the clinical staff of the unit.

### Conflict of interest

The authors declare no conflict of interest.

### References

1. Estudio Nacional de Vigilancia de Infección Nosocomial en Servicios de Medicina Intensiva (ENVIN-HELICS). 2014. Available from: <http://www.semicyuc.org>
2. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. *Ann Intern Med.* 2001;134:298–314.
3. Srigley JA, Brooks A, Sung M, Yamamura D, Haider S, Mertz D. Inappropriate use of antibiotics and *Clostridium difficile* infection. *Am J Infect Control.* 2013;41:1116–8.
4. Elligsen M, Walker SA, Pinto R, Simor A, Mubareka S, Rachlis A, et al. Audit and feedback to reduce broad spectrum antibiotic use among intensive care unit patients: a controlled interrupted time series analysis. *Infect Control Hosp Epidemiol.* 2012;33:354–61.
5. Rimawi RH, Mazer MA, Siraj DS, Gooch M, Cook PP. Impact of regular collaboration between infectious diseases and critical care practitioners on antimicrobial utilization and patient outcome. *Crit Care Med.* 2013;41:2099–107.
6. Mertz D, Brooks A, Irfan N, Sung M. Antimicrobial stewardship in the intensive care setting – a review and critical appraisal of the literature. *Swiss Med Wkly.* 2015;145:w14220.
7. Spelberg B, Srinivasen A, Chambers HF. New societal approaches to empowering antibiotic stewardship. *JAMA.* 2016;315:1229–30.
8. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. *Crit Care Med.* 2013;41:580–637.
9. Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. *Cochrane Database Syst Rev.* 2006;1:CD003344.
10. Barrett J, Edgeworth J, Wyncoll D. Shortening the course of antibiotic treatment in the intensive care unit. *Expert Rev Anti Infect Ther.* 2015;13:463–71.
11. Pantelidou I-M, Giamarellos-Bourboulis EJ. Can procalcitonin monitoring reduce the length of antibiotic treatment in

- bloodstream infections? *Int J Antimicrob Agents*. 2015;46 Suppl. 1:S10-2.
12. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. *Clin Pharmacokinet*. 2006;45:755–73.
  13. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESCAPE! An update from the Infectious Diseases Society of America. *Clin Infect Dis*. 2009;48:1–12.